Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

Lancet Oncology

Volumn 6, Issue 4, 2005, Pages 249-251

  Wardelmann, Eva ^a,d   Thomas, Nadja ^a   Merkelbach Bruse, Sabine ^a   Pauls, Katharina ^a   Speidel, Nicola ^a   Büttner, Reinhard ^a   Bihl, Heiner ^b   Leutner, Claudia C ^a   Heinicke, Thomas ^a   Hohenberger, Peter ^c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b St Katharinen Hospital   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CODON; COMPUTER ASSISTED TOMOGRAPHY; DNA EXTRACTION; DRUG RESPONSE; DRUG TARGETING; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; LIVER METASTASIS; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PERITONEUM METASTASIS; POINT MUTATION; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROPERITONEAL CANCER; SEQUENCE ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 20144387198     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70097-8     Document Type: Article

References (9)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-10.
3. van Osteroom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: A phase I study. Lancet 2001; 358: 1421-23
4. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003; 21: 4342-49
5. Wakai T, Kanda T, Hirota S, et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004; 90: 2059-61
6. Tamborini E, Bonadiman I, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumour patient. Gastroenterology 2004; 127: 294-99.
7. Demetri GD, Desai J, Fletcher J, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 2004; 22: S14 (abstr 3001).
8. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 2004; 6: 197-204
9. Andersson LJ, Sögren H, Meis-Kindblom JM, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002; 160: 15-22